These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Targeting the 3CLpro and RdRp of SARS-CoV-2 with phytochemicals from medicinal plants of the Andean Region: molecular docking and molecular dynamics simulations. Mosquera-Yuqui F; Lopez-Guerra N; Moncayo-Palacio EA J Biomol Struct Dyn; 2022 Mar; 40(5):2010-2023. PubMed ID: 33084512 [TBL] [Abstract][Full Text] [Related]
5. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL Alamri MA; Tahir Ul Qamar M; Mirza MU; Bhadane R; Alqahtani SM; Muneer I; Froeyen M; Salo-Ahen OMH J Biomol Struct Dyn; 2021 Aug; 39(13):4936-4948. PubMed ID: 32579061 [TBL] [Abstract][Full Text] [Related]
6. In Silico Identification of Potential Natural Product Inhibitors of Human Proteases Key to SARS-CoV-2 Infection. Vivek-Ananth RP; Rana A; Rajan N; Biswal HS; Samal A Molecules; 2020 Aug; 25(17):. PubMed ID: 32842606 [TBL] [Abstract][Full Text] [Related]
7. Computational Evidences of Phytochemical Mediated Disruption of PLpro Driven Replication of SARS-CoV-2: A Therapeutic Approach against COVID-19. Balkrishna A; Mittal R; Arya V Curr Pharm Biotechnol; 2021; 22(10):1350-1359. PubMed ID: 33176643 [TBL] [Abstract][Full Text] [Related]
8. In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials. Gul S; Ozcan O; Asar S; Okyar A; Barıs I; Kavakli IH J Biomol Struct Dyn; 2021 Oct; 39(17):6772-6791. PubMed ID: 32752938 [TBL] [Abstract][Full Text] [Related]
9. Computational Search for Potential COVID-19 Drugs from Ayurvedic Medicinal Plants to Identify Potential Inhibitors against SARS-CoV-2 Targets. Alagarsamy V; Solomon VR; Sundar PS; Kulkarni VS; Sulthana MT; Aishwarya AD; Narendhar B; Murugesan S Curr Comput Aided Drug Des; 2023; 19(1):51-67. PubMed ID: 36424783 [TBL] [Abstract][Full Text] [Related]
10. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006 [TBL] [Abstract][Full Text] [Related]
11. Identification of potential phytochemicals from Khan J; Sakib SA; Mahmud S; Khan Z; Islam MN; Sakib MA; Emran TB; Simal-Gandara J J Biomol Struct Dyn; 2022; 40(21):10741-10752. PubMed ID: 34278965 [TBL] [Abstract][Full Text] [Related]
12. Mechanistic Aspects of Medicinal Plants and Secondary Metabolites against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Malekmohammad K; Rafieian-Kopaei M Curr Pharm Des; 2021; 27(38):3996-4007. PubMed ID: 34225607 [TBL] [Abstract][Full Text] [Related]
13. Proposing a fungal metabolite-flaviolin as a potential inhibitor of 3CL Rao P; Shukla A; Parmar P; Rawal RM; Patel BV; Saraf M; Goswami D J Biomol Struct Dyn; 2022 Jan; 40(1):348-360. PubMed ID: 32875950 [TBL] [Abstract][Full Text] [Related]
14. Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an Pandey P; Rane JS; Chatterjee A; Kumar A; Khan R; Prakash A; Ray S J Biomol Struct Dyn; 2021 Oct; 39(16):6306-6316. PubMed ID: 32698689 [TBL] [Abstract][Full Text] [Related]
15. Screening of phytochemical compounds of Krupanidhi S; Abraham Peele K; Venkateswarulu TC; Ayyagari VS; Nazneen Bobby M; John Babu D; Venkata Narayana A; Aishwarya G J Biomol Struct Dyn; 2021 Sep; 39(15):5799-5803. PubMed ID: 32627715 [TBL] [Abstract][Full Text] [Related]
16. In silico investigation of phytoconstituents from Indian medicinal herb ' Chowdhury P J Biomol Struct Dyn; 2021 Oct; 39(17):6792-6809. PubMed ID: 32762511 [TBL] [Abstract][Full Text] [Related]
18. Potential phytochemical inhibitors of SARS-CoV-2 helicase Nsp13: a molecular docking and dynamic simulation study. Vivek-Ananth RP; Krishnaswamy S; Samal A Mol Divers; 2022 Feb; 26(1):429-442. PubMed ID: 34117992 [TBL] [Abstract][Full Text] [Related]
19. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease. Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315 [TBL] [Abstract][Full Text] [Related]
20. Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target. Arun KG; Sharanya CS; Abhithaj J; Francis D; Sadasivan C J Biomol Struct Dyn; 2021 Aug; 39(13):4647-4658. PubMed ID: 32571168 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]